GlassScriptPhysician profile
Nicholas Gaultney
NPI 1912356197
$2,010.41
in general payments reported to CMS, 2019-2025
24 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $963 · 2023: $351 · 2024: $202 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.74 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $286.41 | 2021-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.56 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $206.76 | 2023-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $180.69 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Axsome Therapeutics, INC. | $129.99 | 2025 | Sunosi, Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $90.18 | 2021 | |
| Tris Pharma INC | $63.87 | 2021-2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $61.01 | 2021 | |
| Lundbeck LLC | $52.51 | 2021-2025 | Rexulti |
| Corium, LLC | $46.19 | 2023-2024 | Azstarys |
| Adlon Therapeutics L.P. | $41.12 | 2021 | |
| Alkermes, INC. | $40.45 | 2023 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $34.82 | 2021 | |
| Bausch Health US, LLC | $33.50 | 2023-2024 | Aplenzin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $30.32 | 2021-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $21.48 | 2021 | |
| Neurocrine Biosciences, INC. | $18.11 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.87 | 2024 | |
| Eisai INC. | $15.39 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.38 | 2025 | Relexxii |
| Almatica Pharma LLC | $13.90 | 2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $13.58 | 2021 | |
| Noven Therapeutics, LLC | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Gaultney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.